Catatan sumber primer
PenentuHasil topline
Kodiak DAYBREAK Phase 3 topline untuk Zenkuda dan KSI-501 diharapkan September 2026
8-K mengonfirmasi bahwa studi DAYBREAK Phase 3 Zenkuda dan KSI-501 pada wet AMD yang belum pernah diobati tetap sesuai jadwal untuk data topline endpoint primer satu tahun pada September 2026. Pendaftaran telah selesai dan perusahaan melanjutkan kegiatan persiapan BLA untuk Zenkuda. Pembacaan Phase 3 kedua untuk KSI-101 pada MESI juga dipandu untuk Desember 2026.
Fakta utama
- Diajukan
- 13 Agu 2026, 20.00
- Peristiwa
- Hasil topline
- Arah
- Netral
- Perusahaan
KODKodiak Sciences- Aset
- Zenkuda
- Sumber
- SEC 8-K
- Keyakinan
- Bersumber
- Perbaikan 2 langkah DRSS
- 62.5% berbanding 3.3% (p<0.0001)
- Penurunan risiko STC
- 85% (2.4% berbanding 15.8%, p=0.0001)
Kutipan sumber
EX-99.1 2 kod-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results PALO ALTO, Calif., August 13, 2026 -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended June 30, 2026. "Kodiak continues to execute broadly across our late-stage clinical portfolio as we approach three Phase 3 readouts between now and the end of this year," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "We remain on track for September 2026 DAYBREAK Phase 3 topline results evaluating both Zenkuda and KSI-501 in treatment-naïve wet AMD, followed by December 2026 PEAK Phase 3 Pivotal Analysis 1 topline results evaluating KSI-101 in Macular